Kestra Private Wealth Services LLC Sells 3,989 Shares of Edwards Lifesciences Co. (NYSE:EW)

Kestra Private Wealth Services LLC reduced its position in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 29.9% in the first quarter, HoldingsChannel.com reports. The firm owned 9,360 shares of the medical research company’s stock after selling 3,989 shares during the period. Kestra Private Wealth Services LLC’s holdings in Edwards Lifesciences were worth $1,102,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. boosted its position in shares of Edwards Lifesciences by 7.6% during the fourth quarter. BlackRock Inc. now owns 57,040,983 shares of the medical research company’s stock worth $7,389,659,000 after acquiring an additional 4,007,132 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Edwards Lifesciences by 1.3% during the first quarter. Vanguard Group Inc. now owns 49,724,866 shares of the medical research company’s stock worth $5,853,612,000 after acquiring an additional 648,217 shares during the last quarter. State Street Corp boosted its position in shares of Edwards Lifesciences by 3.7% during the fourth quarter. State Street Corp now owns 26,920,713 shares of the medical research company’s stock worth $3,487,578,000 after acquiring an additional 948,638 shares during the last quarter. Capital International Investors boosted its position in shares of Edwards Lifesciences by 1.0% during the first quarter. Capital International Investors now owns 22,150,133 shares of the medical research company’s stock worth $2,607,436,000 after acquiring an additional 218,908 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Edwards Lifesciences by 4.6% during the fourth quarter. Alliancebernstein L.P. now owns 13,398,520 shares of the medical research company’s stock worth $1,735,778,000 after acquiring an additional 583,209 shares during the last quarter. 81.33% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,725 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $90.94, for a total transaction of $611,571.50. Following the transaction, the vice president now directly owns 62,561 shares in the company, valued at approximately $5,689,297.34. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the firm’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $90.94, for a total value of $611,571.50. Following the sale, the vice president now directly owns 62,561 shares in the company, valued at approximately $5,689,297.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Larry L. Wood sold 7,242 shares of the firm’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $95.90, for a total transaction of $694,507.80. Following the completion of the sale, the vice president now owns 202,232 shares in the company, valued at $19,394,048.80. The disclosure for this sale can be found here. Insiders have sold a total of 66,253 shares of company stock worth $6,550,960 in the last three months. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Cowen decreased their price target on shares of Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. StockNews.com raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 17th. Cowen decreased their price target on shares of Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. Canaccord Genuity Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $115.00 to $106.00 in a research note on Friday, July 29th. Finally, Morgan Stanley decreased their price target on shares of Edwards Lifesciences from $136.00 to $119.00 and set an “overweight” rating on the stock in a research note on Friday, July 15th. Three investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $126.19.

Edwards Lifesciences Trading Down 1.6 %

EW stock opened at $93.35 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.37 and a quick ratio of 2.60. Edwards Lifesciences Co. has a 12 month low of $85.58 and a 12 month high of $131.73. The firm’s 50-day moving average is $98.20 and its 200 day moving average is $102.50. The company has a market capitalization of $57.87 billion, a PE ratio of 40.41, a P/E/G ratio of 2.80 and a beta of 1.14.

Edwards Lifesciences (NYSE:EWGet Rating) last issued its earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by ($0.01). Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the previous year, the company earned $0.64 earnings per share. The firm’s revenue was down .2% on a year-over-year basis. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.51 EPS for the current year.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Stories

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWGet Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.